# US 2014/0193401 A1 · Pertussis antibodies and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193401 A1 - Document ID: US20140193401A1 - Status: Published application - Kind: A1 - Application number: 14/135,353 - Filed: 2013-12-19 - Published: 2014-07-10 - Earliest claimed: 2010-09-17 - Assignees: Board of Regents, The University of Texas System - Applicants: Board of Regents, The University of Texas System - Inventors: Jennifer A. Maynard; Jamie Sutherland - Web page: https://patentgrep.com/patent/US20140193401A1 ## CPC - C07K 16/1225: {from Bordetella (G)} - A61P 31/04: Antibacterial agents - A61P 37/04: Immunostimulants - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/55: Fab or Fab' - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/622: Single chain antibody (scFv) - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided. ## Claims ### Claim at position 1 -65. (canceled) ### Claim 66 A humanized antibody capable of binding a pertussis toxin protein, the humanized antibody comprising a humanized heavy chain and a humanized light chain, wherein said humanized light chain comprises a phenylalanine at a position corresponding to Kabat position 65. ### Claim 67 (depends on 66) The humanized antibody of claim 66, wherein the antibody is a Fab′ fragment. ### Claim 68 (depends on 66) The humanized antibody of claim 66, wherein the antibody comprises a human constant region. ### Claim 69 (depends on 66) The humanized antibody of claim 66, wherein the antibody is an IgG. ### Claim 70 (depends on 66) The humanized antibody of claim 66, wherein the antibody is a single chain antibody (scFv). ### Claim 71 (depends on 66) The humanized antibody of claim 66, wherein the antibody is capable of binding said pertussis toxin protein with an equilibrium dissociation constant (KD) less than 10 nM. ### Claim 72 (depends on 71) The humanized antibody of claim 71, wherein said pertussis toxin protein is a truncated pertussis toxin protein. ### Claim 73 (depends on 72) The humanized antibody of claim 72, wherein said truncated pertussis toxin protein comprises the amino acid sequence corresponding to amino acid residues 1 to 220 of SEQ ID NO:9. ### Claim 74 (depends on 71) The humanized antibody of claim 71, wherein the humanized antibody is an antibody which competes with an antibody that is capable of binding a pertussis toxin protein comprising the amino acid sequence corresponding to amino acid residues 1 to 220 of SEQ ID NO:9. ### Claim 75 (depends on 66) The humanized antibody of claim 66, wherein the antibody is capable of binding a 1B7 footprint region. ### Claim 76 (depends on 75) The humanized antibody of claim 75, wherein the 1B7 footprint region comprises an arginine at a position corresponding to position 79 of SEQ ID NO:9. ### Claim 77 (depends on 75) The humanized antibody of claim 75, wherein the 1B7 footprint region comprises a histidine at a position corresponding to position 83 of SEQ ID NO:9. ### Claim 78 (depends on 75) The humanized antibody of claim 75, wherein the 1B7 footprint region comprises a tyrosine at a position corresponding to position 148 of SEQ ID NO:9. ### Claim 79 (depends on 75) The humanized antibody of claim 75, wherein the 1B7 footprint region comprises an asparagine at a position corresponding to position 150 of SEQ ID NO:9. ### Claim 80 (depends on 75) The humanized antibody of claim 75, wherein the 1B7 footprint region comprises the amino acid sequence in SEQ ID NO:9. ### Claim 81 A pharmaceutical composition comprising a therapeutically effective amount of a humanized antibody capable of binding a pertussis toxin protein and a pharmaceutically acceptable excipient, wherein humanized antibody comprises a humanized heavy chain and a humanized light chain, wherein said humanized light chain comprises a phenylalanine at a position corresponding to Kabat position 65. ### Claim 82 A method of treating whooping cough in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a humanized antibody capable of binding a pertussis toxin protein and a pharmaceutical carrier, thereby treating whooping cough in the subject, wherein humanized antibody comprises a humanized heavy chain and a humanized light chain, wherein said humanized light chain comprises a phenylalanine at a position corresponding to Kabat position 65.